Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus
Anna Kanerva(University of Helsinki), Akseli Hemminki(University of Helsinki), Taco G. Uil(Leiden University Medical Center), Kurt R. Zinn(University of Alabama at Birmingham), Kaori Suzuki(Juntendo University), Zhihong Cao(University of Helsinki), Minghui Wang(Center for Genomic Science), Bin Liu(University of Minnesota), John Lam, Tandra R. Chaudhuri(University of Helsinki), Gerd Bauerschmitz, Ronald D. Alvarez(Vanderbilt University Medical Center), Tanja Hakkarainen(University of Eastern Finland), David T. Curiel(Washington University in St. Louis)
Cited by 172
Related Papers
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k
An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism
|Journal of Virology|1998|769
Engineering targeted viral vectors for gene therapy
|Nature Reviews Genetics|2007|678
Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function
|The Journal of Immunology|2006|487